Walden Group Healthcare M&A Blog

  • Intersect ENT to Acquire Fiagon AG Medical Technologie

    9/25/2020
    Intersect ENT (Nasdaq: XENT), a $109.1m developer of sinus implants and other ENT-focused products is acquiring Germany-based Fiagon, a developer of proprietary, electromagnetic-based ENT surgical navigation systems for $71.2m.  Fiagon’s instruments, produced in Germany, are tip-tracked, enabling surgeons to monitor the full range of...
    Read More
  • Bruker To Acquire Canopy Biosciences

    9/14/2020
    Bruker Corp. (Nasdaq: BRKR), a $2.1b manufacturer of analytical and diagnostic platforms and instruments is acquiring Canopy Biosciences, a developer of multiplex biomarker imaging technologies for immunology, immuno-oncology and cell therapy to boost Bruker’s CRISPR (clustered regularly interspaced short palindromic repeats) gene editing...
    Read More
  • Royal Philips to Acquire Intact Vascular for $360m

    9/8/2020
    Koninklijke Philips NV (Royal Philips) (NYSE: PHG), a $19.5b Netherlands-based producer of medical technologies and imaging platforms is acquiring Intact Vascular, Inc., a developer of a minimally invasive implantable device to treat Peripheral Artery Disease (PAD), when narrowed blood vessels restrict blood flow to limbs.  The acquisition...
    Read More
  • Hologic Acquires Acessa Health for $80M

    9/1/2020
    Hologic (Nasdaq: HOLX), a $3.4b developer of diagnostics, imaging systems, surgical products, and light-based aesthetic and medical treatment platforms for women is buying Acessa Health, the developer of the Acessa ProVu system, a laparoscopic device combining radiofrequency ablation and advanced intra-abdominal ultrasound to treat benign uterine...
    Read More
  • Thermo Fisher Terminates $12.4b Planned Purchase of Qiagen

    8/27/2020
    After Thermo Fisher originally announced a $11.5b takeover bid for Netherlands-based Qiagen in March, an amended $12.4b acquisition proposal has since lapsed in accordance with its terms, terminating the deal.    A campaign against the deal spear-headed by institutional investor Davidson Kempner Capital which owned a 3% stake in Qiagen as of...
    Read More